Produção Nacional
Revisado por pares
1064P Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma
2021; Elsevier BV; Volume: 32; Linguagem: Inglês
10.1016/j.annonc.2021.08.1449
ISSN1569-8041
AutoresRodrigo Ramella Munhoz, Veridiana Pires de Camargo, Guilherme Nader Marta, Marcello Moro Queiroz, Jade Cury‐Martins, Mirella Nardo, Caroline Chaul-Barbosa, Hermínia Ricci, Marcela Rodrigues de Mattos, T.A.F. de Menezes, Guilherme Urano Machado, Eduardo Bertolli, Milton Barros, F. Franke, Fábio de Oliveira Ferreira, Olavo Feher, Gustavo de Castro,
Tópico(s)CAR-T cell therapy research
ResumoImmune checkpoint blockade has emerged as a novel treatment option for patients (pts) with advanced cutaneous squamous cell carcinoma (AcSCC). Here, we present the final results of a single-arm, phase II study of the anti-PD-1 agent nivolumab (NIVO) in pts with advanced AcSCC.
Referência(s)